Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

Treatment with cisplatin (DDP) is one of the standard therapies used to treat non-small-cell lung cancer (NSCLC) and fundamentally causes resistance in cancer cells, which eventually poses as an obstacle to the efficacy of chemotherapy in NSCLC. Efforts are on all over the world to explore a sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Bin, Wei, Ting, Huang, Yuanyuan, Gong, Yuxin, Wu, Gang, Liu, Junfang, Chen, Xiaoting, Shi, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931030/
https://www.ncbi.nlm.nih.gov/pubmed/31915416
http://dx.doi.org/10.1155/2019/7241418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931030/
https://www.ncbi.nlm.nih.gov/pubmed/31915416
http://dx.doi.org/10.1155/2019/7241418

Ejemplares similares